JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) - Total Assets

Latest as of September 2025: Rs47.12 Billion INR ≈ $509.63 Million USD

Based on the latest financial reports, JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) holds total assets worth Rs47.12 Billion INR (≈ $509.63 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) net assets for net asset value and shareholders' equity analysis.

JB Chemicals & Pharmaceuticals Limited - Total Assets Trend (2005–2025)

This chart illustrates how JB Chemicals & Pharmaceuticals Limited's total assets have evolved over time, based on quarterly financial data.

JB Chemicals & Pharmaceuticals Limited - Asset Composition Analysis

Current Asset Composition (March 2025)

JB Chemicals & Pharmaceuticals Limited's total assets of Rs47.12 Billion consist of 45.0% current assets and 55.0% non-current assets.

Asset Category Amount (INR) % of Total Assets
Cash & Equivalents Rs360.00 Million 3.0%
Accounts Receivable Rs9.02 Billion 21.1%
Inventory Rs5.29 Billion 12.4%
Property, Plant & Equipment Rs6.57 Billion 15.4%
Intangible Assets Rs13.17 Billion 30.8%
Goodwill Rs574.60 Million 1.3%

Asset Composition Trend (2005–2025)

This chart illustrates how JB Chemicals & Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see JBCHEPHARM stock market capitalisation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: JB Chemicals & Pharmaceuticals Limited's current assets represent 45.0% of total assets in 2025, a decrease from 66.5% in 2005.
  • Cash Position: Cash and equivalents constituted 3.0% of total assets in 2025, up from 0.0% in 2005.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 0.0% in 2005.
  • Asset Diversification: The largest asset category is intangible assets at 30.8% of total assets.

JB Chemicals & Pharmaceuticals Limited Competitors by Total Assets

Key competitors of JB Chemicals & Pharmaceuticals Limited based on total assets are shown below.

Company Country Total Assets
Daihan Pharmaceutical Co.Ltd
KQ:023910
Korea ₩344.02 Billion
Aurobindo Pharma Limited
NSE:AUROPHARMA
India Rs525.46 Billion
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
China CN¥56.56 Billion
Ningbo Menovo Pharm Co Ltd
SHG:603538
China CN¥4.75 Billion
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
China CN¥7.26 Billion
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
China CN¥2.26 Billion
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
China CN¥1.69 Billion
Hainan Honz Pharmaceutical Co
SHE:300086
China CN¥1.88 Billion

JB Chemicals & Pharmaceuticals Limited - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 3.79 3.08 3.95
Quick Ratio 2.93 2.20 2.86
Cash Ratio 0.15 0.16 0.00
Working Capital Rs18.81 Billion Rs12.91 Billion Rs10.20 Billion

JB Chemicals & Pharmaceuticals Limited - Advanced Valuation Insights

This section examines the relationship between JB Chemicals & Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 7.94
Latest Market Cap to Assets Ratio 0.08
Asset Growth Rate (YoY) 7.0%
Total Assets Rs42.74 Billion
Market Capitalization $3.55 Billion USD

Valuation Analysis

Below Book Valuation: The market values JB Chemicals & Pharmaceuticals Limited's assets below their book value (0.08x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: JB Chemicals & Pharmaceuticals Limited's assets grew by 7.0% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for JB Chemicals & Pharmaceuticals Limited (2005–2025)

The table below shows the annual total assets of JB Chemicals & Pharmaceuticals Limited from 2005 to 2025.

Year Total Assets Change
2025-03-31 Rs42.74 Billion
≈ $462.19 Million
+7.00%
2024-03-31 Rs39.94 Billion
≈ $431.95 Million
+12.39%
2023-03-31 Rs35.54 Billion
≈ $384.34 Million
+36.30%
2022-03-31 Rs26.07 Billion
≈ $281.98 Million
+16.50%
2021-03-31 Rs22.38 Billion
≈ $242.04 Million
+23.41%
2020-03-31 Rs18.14 Billion
≈ $196.13 Million
+1.26%
2019-03-31 Rs17.91 Billion
≈ $193.69 Million
+1.48%
2018-03-31 Rs17.65 Billion
≈ $190.87 Million
+5.43%
2017-03-31 Rs16.74 Billion
≈ $181.04 Million
+7.49%
2016-03-31 Rs15.57 Billion
≈ $168.43 Million
+4.72%
2015-03-31 Rs14.87 Billion
≈ $160.84 Million
+10.08%
2014-03-31 Rs13.51 Billion
≈ $146.11 Million
+3.91%
2013-03-31 Rs13.00 Billion
≈ $140.61 Million
+8.55%
2012-03-31 Rs11.98 Billion
≈ $129.54 Million
+19.85%
2011-03-31 Rs9.99 Billion
≈ $108.08 Million
+19.40%
2010-03-31 Rs8.37 Billion
≈ $90.51 Million
+12.15%
2009-03-31 Rs7.46 Billion
≈ $80.71 Million
+0.68%
2008-03-31 Rs7.41 Billion
≈ $80.17 Million
+4.07%
2007-03-31 Rs7.12 Billion
≈ $77.03 Million
+40.97%
2006-03-31 Rs5.05 Billion
≈ $54.64 Million
+22.85%
2005-03-31 Rs4.11 Billion
≈ $44.48 Million
--

About JB Chemicals & Pharmaceuticals Limited

NSE:JBCHEPHARM India Drug Manufacturers - Specialty & Generic
Market Cap
$3.55 Billion
Rs328.02 Billion INR
Market Cap Rank
#4460 Global
#189 in India
Share Price
Rs2043.40
Change (1 day)
-0.86%
52-Week Range
Rs1504.40 - Rs2138.60
All Time High
Rs2138.60
About

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage … Read more